02102oam 2200565 450 991071143270332120190405132127.0(CKB)5470000002483716(OCoLC)1056703323(EXLCZ)99547000000248371620181012d2018 ua 0engurbn||||a||||txtrdacontentcrdamediacrrdacarrierThe future of transportation fuels and vehicles ;hearing before the Subcommittee on Environment of the Committee on Energy and Commerce, House of Representatives, One Hundred Fifteenth Congress, second session, March 7, 2018Washington :U.S. Government Publishing Office,2018.1 online resource (iii, 120 pages) illustrations, maps"Serial No. 115-106."Includes bibliographical references.Future of transportation fuels and vehicles ; AutomobilesFuel consumptionStandardsUnited StatesMotor vehiclesFuel consumptionStandardsUnited StatesAutomobilesFuel consumptionEnvironmental aspectsUnited StatesRenewable energy sourcesStandardsUnited StatesNatural gas vehiclesUnited StatesVehiclesAutomatic controlEnergy policyUnited StatesLegislative hearings.lcgftAutomobilesFuel consumptionStandardsMotor vehiclesFuel consumptionStandardsAutomobilesFuel consumptionEnvironmental aspectsRenewable energy sourcesStandardsNatural gas vehiclesVehiclesAutomatic control.Energy policyGPOGPOMERUCOCLCFGPONJKOCLCOIASGPOBOOK9910711432703321The future of transportation fuels and vehicles3465660UNINA05264nam 2200697 a 450 991078090110332120230919171543.01-281-30039-X97866113003950-309-11575-2(CKB)2450000000000828(EBL)3378345(SSID)ssj0000400539(PQKBManifestationID)12112065(PQKBTitleCode)TC0000400539(PQKBWorkID)10394776(PQKB)10074069(SSID)ssj0000304393(PQKBManifestationID)12115291(PQKBTitleCode)TC0000304393(PQKBWorkID)10278838(PQKB)10571356(MiAaPQ)EBC3378345(Au-PeEL)EBL3378345(CaPaEBR)ebr10225189(OCoLC)923278682(EXLCZ)99245000000000082819840919d1985 uy 0engur|n|---|||||txtrdacontentcrdamediacrrdacarrierDiseases of importance in the United States /by the Committee on Issues and Priorities for New Vaccine Development, Division of Health Promotion and Disease Prevention, Institute of MedicineWashington, D.C. National Academy Press19851 online resource (472 pages)New vaccine development : establishing priorities ;v. 1Prepared for the National Institute of Allergy and Infectious Diseases.0-309-03494-9 Includes bibliographical references and index.""Title""; ""Copyright""; ""Acknowledgments""; ""Preface""; ""Abstract""; ""Contents""; ""1 Summary""; ""Selection of Candidates""; ""Determination of Health Benefits""; ""Disease Burden Estimates""; ""Infant Mortality Equivalence Values""; ""Total Disease Burden Values""; ""Vaccine Characteristics""; ""Predictions of Vaccine Development""; ""Definition of Probable Vaccine Target Population""; ""Estimation of Vaccine Utilization""; ""Estimation of Time to Licensure, Time to vaccine Adoption, and Delay of Vaccination Benefits: Discounting""; ""Estimation of vaccine Preventable Illness""""Calculation of Expected Health Benefits for Each Vaccine"" ""Cost Calculations""; ""Calculation of Morbidity Costs Averted by the Vaccine""; ""Vaccination Program Costs""; ""Integration of Costs""; ""Interpretation of Health Benefit and Net Cost Rankings""; ""Findings, Conclusions, Recommendations""; ""Recommendation""; ""Reference""; ""2 Priority Setting for Health Related Investments: A Review of Methods""; ""Methods for Project Ranking and Selection""; ""Multiattribute Accounting""; ""Multiattribute Scoring""; ""Decision Analysis With Multiple Objectives""""Cost-Effectiveness and Cost-Utility Analysis"" ""Benefit-Cost Analysis""; ""Selection of an Approach""; ""Issues in Project Ranking Methodologies""; ""Sources of Estimates""; ""Sequential or 'Lexicographic' Methods""; ""Interdependence Among Projects""; ""The 'Portfolio' Question""; ""Summary""; ""References""; ""3 Overview of the Analytic Approach""; ""Method""; ""Interpretation of Results""; ""Guidelines""; ""Definition of Dominance""; ""Step 1""; ""Step 2""; ""Step 3""; ""Step 4""; ""Summary""; ""4 Comparison of Disease Burdens and Costs""""Elements of the System for Comparing Morbidity and Mortality Burdens Arising From various Diseases"" ""Trade-Off Values""; ""Expression of Morbidity and Mortality Burdens""; ""Procedures Used in Deriving Disease Estimates""; ""Limitations of the Current Estimates""; ""Value Judgments in Quantifying Morbidity and Mortality""; ""IME Perspectives used in This Study""; ""The Effect of Adopting Other IME Perspectives""; ""Comparison of Direct Costs Resulting from Diseases""; ""Scope of Cost Calculations""; ""Procedures""; ""Findings""; ""Limitations of the Proposed System""""Summary and Conclusions"" ""Recommendations""; ""References""; ""5 Predictions on Vaccine Development""; ""The Need for Predictions""; ""Selection of Candidates""; ""Vaccine Candidates and Target Populations""; ""Predictions on Vaccine Development""; ""Probability of Successful Development""; ""Cost of Development""; ""Time to Licensure""; ""Comments""; ""Predictions on Vaccine Characteristics""; ""Efficacy""; ""Adverse Reactions""; ""Production Technology, Delivery Requirements, and Cost/Dose""; ""Number of Doses and Route of Administration""; ""Conclusions""; ""6 Assessing the Likely Utilization of New Vaccines""VaccinesResearchGovernment policyVaccinationUnited StatesVaccinationDeveloping countriesVaccinesResearchGovernment policy.VaccinationVaccination614.4/7/0973Institute of Medicine (U.S.).Committee on Issues and Priorities for New Vaccine Development.National Institute of Allergy and Infectious Diseases (U.S.)MiAaPQMiAaPQMiAaPQBOOK9910780901103321Diseases of importance in the United States3717382UNINA